Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of the PI3K Inhibitor BKM120 in Patients With Relapsed Lymphoma

NCT01719250 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT01719250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01719250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of the PI3K Inhibitor BKM120 in Patients With Relapsed Lymphoma
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2012
Completion date
March 22, 2017
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent adult diffuse large cell lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, refractory mantle cell lymphoma, transformed recurrent non-hodgkin lymphoma